Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 15/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22208318 | 0.88 | SQOR (1.00) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL22208456 | 0.88 | SQOR (0.81) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL29442258 | 0.88 | SQOR (0.81) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL29442359 | 0.88 | SQOR (1.00) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL29442279 | 0.85 | SQOR (0.78) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL22208274 | 0.85 | SQOR (0.78) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL22215864 | 0.85 | SQOR (1.00) | SQORADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22208298 | 0.82 | SQOR (0.82) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL22208321 | 0.81 | SQOR (0.70) | SQORADORA2AADORA1KDM4ETDP1 | |
| SCHEMBL29442275 | 0.81 | SQOR (0.70) | SQORADORA2AADORA1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096450-A1 | Compounds and Methods for Treating or Preventing Heart Failure | DREXEL UNIVERSITY | 2022-03-31 | — | — | US | claimed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | claimed |
| US-20220096450-A1 | Compounds and Methods for Treating or Preventing Heart Failure | DREXEL UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146636-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE | DREXEL UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096450-A1 | Compounds and Methods for Treating or Preventing Heart Failure | SQOR, QSOX1, KEAP1 | SQOR 1/4885ADORA2A 2429/4885ADORA1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.